Amneal Pharmaceuticals vs Elanco Animal Health
AMRX and ELAN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and ELAN compare
Elanco Animal Health is the larger company, worth 1.7 times as much as Amneal Pharmaceuticals ($11.5B against $6.9B).
Elanco Animal Health grew revenue faster over the last twelve months (12.0% versus 9.3% for Amneal Pharmaceuticals).
Amneal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with −4.0% at Elanco Animal Health.
Amneal Pharmaceuticals scores higher on the StockData Score (10 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | ELAN |
|---|---|---|
| Size and price | ||
| Market cap | $6.9B | $11.5B |
| Share price | $21.51 | $23.06 |
| Change, 1 year | 106% | 2.1% |
| Change, 5 years | 318% | −32.4% |
| Beta (5Y) | 1.06 | 1.11 |
| Employees | 8,500 | 9,400 |
| StockData Score | ||
| Total score | 10 (better) | 9 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 3 |
| Performance score | 4 (better) | 3 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 43.9× | – |
| P/S | 2.2× (better) | 2.3× |
| P/B | 208× | 1.7× (better) |
| EV/EBITDA | 20.5× (better) | 28.3× |
| P/FCF | 53.7× | 30.4× (better) |
| FCF yield | 1.9% | 3.3% (better) |
| Fair value | $12.75 | $10.92 |
| Margin of safety | −68.7% (better) | −111% |
| Growth | ||
| Revenue growth (TTM) | 9.3% | 12.0% (better) |
| Revenue growth, 5Y average | 8.7% (better) | 7.6% |
| Net income growth (TTM) | 4563% (better) | −146% |
| EPS growth (TTM) | 4800% (better) | −149% |
| EPS growth, 5Y average | −18.5% | – |
| Profitability | ||
| Gross margin | 39.3% | 55.4% (better) |
| Operating margin | 14.6% | – |
| Net margin | 5.0% (better) | −4.0% |
| FCF margin | 4.1% | 7.5% (better) |
| Return on equity | – | −3.0% |
| Return on invested capital | 20.3% | – |
| Financial health | ||
| Debt / equity | 77.83 | 0.59 (better) |
| Net debt / EBITDA | 5.38 (better) | 6.43 |
| Current ratio | 2.20 (better) | 2.05 |
| Altman Z-score | 2.51 (better) | 1.32 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 52.7% | 113% |
| Held by insiders | 60.7% | 1.1% |
| Insider net buying, 12 months | −$9.8M | $2.6M (better) |
| Short interest, % of float | 9.0% | 7.5% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- ELAN stock overview
- ELAN income statement
- ELAN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.